Dr William J Livingston Iii, MD | |
1010 1st St N, Suite 301, Alabaster, AL 35007-8608 | |
(205) 621-8900 | |
(205) 621-7169 |
Full Name | Dr William J Livingston Iii |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Experience | 19 Years |
Location | 1010 1st St N, Alabaster, Alabama |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043233091 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | 30250 (Alabama) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Shelby Baptist Medical Center | Alabaster, AL | Hospital |
Grandview Medical Center | Birmingham, AL | Hospital |
St Vincent's Chilton | Clanton, AL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Shelby Ear Nose And Throat | 7113997073 | 3 |
News Archive
Scientists sound the alarm: Lockdowns may escalate the obesity epidemic Emotional stress, economic anxiety, physical inactivity and social distance - locking down society to combat COVID-19 creates psychosocial insecurity that leads to obesity, warn three Danish researchers.
Eating a Mediterranean diet and following national recommendations for physical activity are each associated with a reduced risk of death over a five-year period, according to two reports in the December 10/24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Nucleic acid testing (NAT) technologies that use real-time polymerase chain reaction (RT-PCR) for detection of SARS-CoV-2.
Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds.
› Verified 2 days ago
Entity Name | Shelby Ear Nose And Throat |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1689770174 PECOS PAC ID: 7113997073 Enrollment ID: O20040728000762 |
News Archive
Scientists sound the alarm: Lockdowns may escalate the obesity epidemic Emotional stress, economic anxiety, physical inactivity and social distance - locking down society to combat COVID-19 creates psychosocial insecurity that leads to obesity, warn three Danish researchers.
Eating a Mediterranean diet and following national recommendations for physical activity are each associated with a reduced risk of death over a five-year period, according to two reports in the December 10/24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Nucleic acid testing (NAT) technologies that use real-time polymerase chain reaction (RT-PCR) for detection of SARS-CoV-2.
Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr William J Livingston Iii, MD 1010 1st St N, Suite 301, Alabaster, AL 35007-8608 Ph: (205) 621-8900 | Dr William J Livingston Iii, MD 1010 1st St N, Suite 301, Alabaster, AL 35007-8608 Ph: (205) 621-8900 |
News Archive
Scientists sound the alarm: Lockdowns may escalate the obesity epidemic Emotional stress, economic anxiety, physical inactivity and social distance - locking down society to combat COVID-19 creates psychosocial insecurity that leads to obesity, warn three Danish researchers.
Eating a Mediterranean diet and following national recommendations for physical activity are each associated with a reduced risk of death over a five-year period, according to two reports in the December 10/24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Nucleic acid testing (NAT) technologies that use real-time polymerase chain reaction (RT-PCR) for detection of SARS-CoV-2.
Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds.
› Verified 2 days ago